Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Ratliff, Brooke; Dietze, Eric C; Bean, Gregory R; Moore, Cassandra; Wanko, Sam; Seewaldt, Victoria L

Ratliff, Brooke; Dietze, Eric C; Bean, Gregory R; Moore, Cassandra; Wanko, Sam; Seewaldt, Victoria L.

J Natl Cancer Inst ; 96(11): 883; author reply 884-5, 2004 Jun 02.

Article in En | MEDLINE | ID: mdl-15173275

Subject(s)

Antineoplastic Agents, Hormonal/blood; Estrogen Receptor Modulators/blood; Paroxetine/administration & dosage; Paroxetine/pharmacology; Selective Serotonin Reuptake Inhibitors/pharmacology; Tamoxifen/analogs & derivatives; Tamoxifen/administration & dosage; Tamoxifen/blood; Antidepressive Agents, Second-Generation/pharmacology; Antineoplastic Agents, Hormonal/administration & dosage; Antineoplastic Agents, Hormonal/pharmacokinetics; Estrogen Receptor Modulators/administration & dosage; Estrogen Receptor Modulators/pharmacokinetics; Female; Humans; Selective Serotonin Reuptake Inhibitors/administration & dosage; Tamoxifen/pharmacokinetics

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Tamoxifen / Selective Serotonin Reuptake Inhibitors / Paroxetine / Antineoplastic Agents, Hormonal / Estrogen Receptor Modulators Limits: Female / Humans Language: En Journal: J Natl Cancer Inst Year: 2004 Document type: Article

Search on Google

Add to My VHL

XML

PubMed Links